Common Contracts
3 similar License Agreement contracts by Spark Therapeutics, Inc.
EX-10.18 21 d776249dex1018.htm EX-10.18 EXECUTION VERSION LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND SPARK THERAPEUTICS, INC. Dated as of December 6, 2014 - i - - ii - - iii - EXHIBITS AND SCHEDULES Exhibit A Product Development Plan Exhibit B...License Agreement • May 5th, 2020 • New York
This License Agreement (the “Agreement”) is entered into and made effective as of December 6, 2014 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and Spark Therapeutics, Inc. a corporation organized and existing under the laws of the State of Delaware with offices at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (“Spark”). Pfizer and Spark are referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND SPARK THERAPEUTICS, INC. Dated as of December 6, 2014License Agreement • December 30th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is entered into and made effective as of December 6, 2014 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and Spark Therapeutics, Inc. a corporation organized and existing under the laws of the State of Delaware with offices at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (“Spark”). Pfizer and Spark are referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND SPARK THERAPEUTICS, INC. Dated as of December 6, 2014License Agreement • December 11th, 2014 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is entered into and made effective as of December 6, 2014 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and Spark Therapeutics, Inc. a corporation organized and existing under the laws of the State of Delaware with offices at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (“Spark”). Pfizer and Spark are referred to herein individually as a “Party” and collectively as the “Parties”.
